Literature DB >> 25772393

Improving the tuberculosis drug development pipeline.

Dimitrios Evangelopoulos1, Timothy D McHugh1.   

Abstract

Mycobacterium tuberculosis is considered one of the most successful pathogens and multidrug-resistant tuberculosis, a disease that urgently requires new chemical entities to be developed for treatment. There are currently several new molecules under clinical investigation in the tuberculosis (TB) drug development pipeline. However, the complex lifestyle of M. tuberculosis within the host presents a barrier to the development of new drugs. In this review, we highlight the reasons that make TB drug discovery and development challenging as well as providing solutions, future directions and alternative approaches to new therapeutics for TB.
© 2015 John Wiley & Sons A/S.

Entities:  

Keywords:  biological screening; drug development; gene expression; mechanism-based drug design; therapeutic target

Mesh：

Substances：

Year:  2015        PMID： 25772393     DOI： 10.1111/cbdd.12549

Source DB:  PubMed          Journal:  Chem Biol Drug Des        ISSN： 1747-0277            Impact factor:   2.817


  10 in total

1.  Structure-Based Optimization of Pyridoxal 5'-Phosphate-Dependent Transaminase Enzyme (BioA) Inhibitors that Target Biotin Biosynthesis in Mycobacterium tuberculosis.

Authors:  Feng Liu; Surendra Dawadi; Kimberly M Maize; Ran Dai; Sae Woong Park; Dirk Schnappinger; Barry C Finzel; Courtney C Aldrich
Journal:  J Med Chem       Date:  2017-06-22       Impact factor: 7.446

Review 2.  Molecule Property Analyses of Active Compounds for Mycobacterium tuberculosis.

Authors:  Vadim Makarov; Elena Salina; Robert C Reynolds; Phyo Phyo Kyaw Zin; Sean Ekins
Journal:  J Med Chem       Date:  2020-04-20       Impact factor: 7.446

Review 3.  Phenazine Antibiotic-Inspired Discovery of Bacterial Biofilm-Eradicating Agents.

Authors:  Robert W Huigens; Yasmeen Abouelhassan; Hongfen Yang
Journal:  Chembiochem       Date:  2019-10-02       Impact factor: 3.164

Review 4.  Anti-tuberculosis treatment strategies and drug development: challenges and priorities.

Authors:  Véronique A Dartois; Eric J Rubin
Journal:  Nat Rev Microbiol       Date:  2022-04-27       Impact factor: 78.297

5.  Structural Rigidification of N-Aryl-pyrroles into Indoles Active against Intracellular and Drug-Resistant Mycobacteria.

Authors:  Dorothy Semenya; Meir Touitou; Camila Maringolo Ribeiro; Fernando Rogerio Pavan; Luca Pisano; Vinayak Singh; Kelly Chibale; Georg Bano; Anita Toscani; Fabrizio Manetti; Beatrice Gianibbi; Daniele Castagnolo
Journal:  ACS Med Chem Lett       Date:  2021-12-08       Impact factor: 4.345

Review 6.  Mass Spectrometry Offers Insight into the Role of Ser/Thr/Tyr Phosphorylation in the Mycobacteria.

Authors:  Bridget Calder; Claudia Albeldas; Jonathan M Blackburn; Nelson C Soares
Journal:  Front Microbiol       Date:  2016-02-12       Impact factor: 5.640

7.  A Collaborative Approach for "ReSeq-ing" Mycobacterium tuberculosis Drug Resistance: Convergence for Drug and Diagnostic Developers.

Authors:  Marco Schito; David L Dolinger
Journal:  EBioMedicine       Date:  2015-10-09       Impact factor: 8.143

Review 8.  Tuberculosis 2015: Burden, Challenges and Strategy for Control and Elimination.

Authors:  Mario Raviglione; Giorgia Sulis
Journal:  Infect Dis Rep       Date:  2016-06-24

Review 9.  Targeting DNA Replication and Repair for the Development of Novel Therapeutics against Tuberculosis.

Authors:  Michael A Reiche; Digby F Warner; Valerie Mizrahi
Journal:  Front Mol Biosci       Date:  2017-11-14

10.  A Highly Potent Class of Halogenated Phenazine Antibacterial and Biofilm-Eradicating Agents Accessed Through a Modular Wohl-Aue Synthesis.

Authors:  Hongfen Yang; Yasmeen Abouelhassan; Gena M Burch; Dimitris Kallifidas; Guangtao Huang; Hussain Yousaf; Shouguang Jin; Hendrik Luesch; Robert W Huigens
Journal:  Sci Rep       Date:  2017-05-17       Impact factor: 4.379
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.